Dipexium Pharmaceuticals Inc. (NASDAQ:DPRX) shares reached a new 52-week high on Tuesday . The stock traded as high as $15.40 and last traded at $15.20, with a volume of 30,143 shares traded. The stock had previously closed at $14.70.

Separately, Zacks Investment Research raised Dipexium Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, June 14th.

The stock has a 50 day moving average of $12.78 and a 200-day moving average of $10.82. The company’s market cap is $157.01 million.

Dipexium Pharmaceuticals (NASDAQ:DPRX) last announced its earnings results on Thursday, August 4th. The company reported ($0.52) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.54) by $0.02. Equities research analysts expect that Dipexium Pharmaceuticals Inc. will post ($2.10) EPS for the current fiscal year.

Hedge funds and other institutional investors have recently bought and sold shares of the company. Lombard Odier Asset Management USA Corp acquired a new position in Dipexium Pharmaceuticals during the second quarter valued at $1,507,000. Raymond James & Associates acquired a new position in Dipexium Pharmaceuticals during the second quarter valued at $312,000. Timpani Capital Management LLC raised its position in Dipexium Pharmaceuticals by 45.4% in the second quarter. Timpani Capital Management LLC now owns 64,124 shares of the company’s stock valued at $635,000 after buying an additional 20,014 shares during the period. BlackRock Fund Advisors raised its position in Dipexium Pharmaceuticals by 19.6% in the second quarter. BlackRock Fund Advisors now owns 15,674 shares of the company’s stock valued at $155,000 after buying an additional 2,568 shares during the period. Finally, Vanguard Group Inc. raised its position in Dipexium Pharmaceuticals by 8.7% in the second quarter. Vanguard Group Inc. now owns 158,297 shares of the company’s stock valued at $1,569,000 after buying an additional 12,670 shares during the period. 24.78% of the stock is owned by hedge funds and other institutional investors.

Dipexium Pharmaceuticals Company Profile

Dipexium Pharmaceuticals, Inc is a late-stage pharmaceutical company. The Company is focused on the development and commercialization of Locilex (pexiganan cream 0.8%), a first-in-class, broad spectrum, topical antibiotic. Locilex is focused on the treatment of mild infections of diabetic foot ulcers (Mild DFI).

5 Day Chart for NASDAQ:DPRX

Receive News & Ratings for Dipexium Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dipexium Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.